Patient P-02517
Synthetic patientMETA-24 · Day 173 · 55–64 · M · baseline S12Steering view · 3DOpen companion preview
Therapy response
Improving
Tolerance
Improving
GI state
Deteriorating
Inflammatory state
Favorable
Nutritional resilience
Favorable
Discontinuation risk
21%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S12
- Day 113 Trajectory diverged from prediction — Observed response fell below the model's expected path.
What changed?
Trajectory began diverging from predicted response on Day 113.
Primary contributors, last 14 days
- Toxicity-19
- GI instability+4
- Inflammatory activity-3
- Nutritional resilience-2
- Treatment adherence-2
What helped?
No interventions yet.
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Active minutes
Wearable55 min
stable · +1.2 vs previous 14 d
Sleep duration
Wearable6.4 h
stable · -0.1 vs previous 14 d
Energy level
Daily log5.3/10
improving · +0.7 vs previous 14 d
Steps
Wearable5,735
stable · +122 vs previous 14 d
GI burden
Companion22.5/100
improving · -5.0 vs previous 14 d
Adherence
Companion81.3 %
stable · +2.0 vs previous 14 d
Sleep quality
Wearable47.4/100
improving · +2.8 vs previous 14 d
Glucose, CGM daily mean
CGM125 mg/dL
stable · -2.1 vs previous 14 d
This trajectory is doing well — what to keep, what to watch
Steering view →Heading towards restoration · 70 from the failing basin, 30 from restoration.
Good elements to keep
- Butyrate producers intacthidden · steering +7.5
- Protein (supports)perturbation · steering +6.6
- Proteinsupporter · GI -3.7 next day
Main detractors to watch
- Antibiotic courseperturbation · steering -4.7
- Dietary driftperturbation · steering -2.6
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Protein-3.7supporter · 95%
- Insoluble fibre-1.1no signal · 29%
- Ultra-processed food+1.1no signal · 31%
- Histamine load+0.9no signal · 30%
- Caffeine+0.7no signal · 20%
- Alcohol+0.7no signal · 19%
- Dietary fat load-0.2no signal · 15%
- Simple carbohydrates+0.1no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓30
- MicrobiomeAkkermansia low → thinner mucus layer
- Autonomic recovery ↓20
- WearableShort sleep window
DNA
Fictional pharmacogenomic panel
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 3.9 · butyrate capacity 58/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 61 ms
- Sleep
- 6.2 h
- Steps
- 6,564
- Resting HR
- 70 bpm
Daily log: GI score 23, nutritional resilience 66, adherence 81.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Keep fibre steady; no new sources this week
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Log the daily check-in; one line is enough
- Keep the current walking rhythm
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02698 | 33% | S06 | ME-01 | improved | 71 |
| P-02214 | 33% | S08 | SC-12 | no change | 69 |
| P-02356 | 32% | S08 | — | — | 69 |
| P-02293 | 32% | S15 | HY-01 | no change | 68 |
| P-02442 | 32% | S14 | — | — | 68 |
| P-02463 | 33% | S18 | — | — | 68 |
| P-02637 | 32% | S11 | — | — | 67 |
| P-02658 | 33% | S04 | — | — | 66 |
| P-02095 | 34% | S08 | — | — | 66 |
| P-02495 | 32% | S05 | — | — | 66 |
| P-02462 | 32% | S12 | DT-01 | improved | 65 |
| P-02476 | 35% | S05 | — | — | 65 |